Knight Therapeutics Target Price for 2026

Knight Therapeutics

TSX:GUD

C$ 7,54

+ C$0,08 (1,07%)

7,54 C$

+C$0,08 (1,07%)

End-of-day quote: 04/24/2026

Knight Therapeutics Stock Value

According to analysts, the current valuation of TSX:GUD is Outperform.

Outperform

Knight Therapeutics Company Info

EPS Growth 5Y

-38,10%

Market Cap

C$0,73 B

Long-Term Debt

C$0,05 B

Short Interest

26,37%

Quarterly earnings

05/07/2026

Dividend

C$0,00

Dividend Yield

0,00%

Founded

2013

Industry

Health Care

Country

Canada

ISIN Number

CA4990531069

Website

http://www.knighttx.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

C$8,25

9.42%

Last Update: 04/24/2026

Analysts: 6

Highest Price Target C$11,00

Average Price Target C$8,25

Lowest Price Target C$6,15

In the last five quarters, Knight Therapeutics’s Price Target has risen from C$7,04 to C$7,66 - a 8,81% increase. Three analysts predict that Knight Therapeutics’s share price will increase in the coming year, reaching C$8,25. This would represent an increase of 9,42%.

Top growth stocks in the health care sector (5Y.)

What does Knight Therapeutics do?

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices. Business Segments The company operates Innovative Drugs, Branded Generics, and Life Sciences Venture Capital Investments segments. Innovative Drugs Innovative Drugs segment encompasses the development and marketing of new pharmaceuticals that are distinguished by their novel mechanisms of action or unique delivery sys...

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices.

Business Segments

The company operates Innovative Drugs, Branded Generics, and Life Sciences Venture Capital Investments segments.

Innovative Drugs

Innovative Drugs segment encompasses the development and marketing of new pharmaceuticals that are distinguished by their novel mechanisms of action or unique delivery systems. These products are typically derived from research collaborations or acquisitions from other biopharmaceutical companies. One crucial factor contributing to this segment's success is the regulatory approval for marketing by major health authorities like Health Canada, the FDA, and the EMA, allowing the company to leverage a reliable portfolio of products addressing critical healthcare issues.

Branded Generics

Branded Generics segment involves bringing to market generic versions of branded drugs that have lost patent protection. These generics are typically produced under license agreements with original brand manufacturers and aim to provide the same therapeutic benefits at a lower cost. The company focuses on securing a robust generics defense strategy, which includes portfolio diversification and maintaining competitive pricing to navigate challenges posed by generic competition.

Life Sciences Venture Capital Investments

Life Sciences Venture Capital Investments segment is another pivotal aspect of its operations. The company actively invests in life sciences venture capital funds and develops partnerships to access innovative healthcare products globally.

Business Strategy

The company's strategy centers around the identification and acquisition of medications that fulfill unmet medical needs, particularly in underserved markets.

The company recognizes the importance of regulatory compliance and maintains strong relationships with health authorities to ensure seamless product approvals. This strategy involves not just responding to existing healthcare demands, but also anticipating future needs by investing in R&D initiatives. Moreover, the company remains focused on risk management, continually assessing market dynamics and regulatory frameworks, allowing it to make informed investment decisions.

Products and Services

The company delivers an extensive range of pharmaceutical products across multiple therapeutic areas, including pain management, neurology, and cardiology. The product portfolio is divided into Innovative Drugs and Branded Generics, each serving a different but complementary role within the healthcare continuum.

Innovative Drugs

The company’s Innovative Drug offerings include novel therapies developed from extensive research collaborations. These treatments often address complex conditions and are distinguished by their unique active ingredients. The company strives to ensure comprehensive product labeling and education to maximize the understanding and safe use of its innovative drugs.

Branded Generics

The Branded Generics product line includes licensed generic medications that are clinically equivalent to their branded counterparts. These products provide a vital alternative for patients while supporting the healthcare landscape by lowering treatment costs. The company emphasizes the quality and safety of its generics, ensuring they meet all regulatory requirements.

Geographical Markets Served

The company primarily serves the Canadian market and several countries in LATAM, which presents a range of unique opportunities and challenges. The company recognizes the critical need to adapt its strategies and products to meet the specific health requirements and regulations of each market.

Seasonality

The company operates in an industry characterized by diverse seasonal trends based on healthcare needs, regulatory approval timelines, and market conditions. Seasonality in the pharmaceutical sector can influence sales patterns, where certain products may see increased demand during specific times of the year. For example, medications related to flu and illness may yield higher sales during colder months. Understanding these seasonal variations enables the company to optimize inventory management and marketing strategies appropriately.

Customers Names

The company serves a diverse clientele, comprising healthcare institutions, hospitals, pharmacies, and healthcare professionals focusing on improving patient outcomes through effective medication. The customer categories include public and private sector healthcare providers, ensuring a wide-ranging distribution network capable of reaching various patient populations. The specific number of customers served by the company remains proprietary; however, the company is committed to expanding its clientele through enhanced product offerings and market penetration strategies.

Modes of Sales and Marketing

The company employs a multifaceted marketing strategy, combining digital, direct, and indirect marketing initiatives to reach healthcare providers and end-users effectively. The distribution model includes partnerships with wholesalers and other pharmaceutical distributors to ensure the timely and efficient delivery of products to markets served. The company also establishes direct relationships with healthcare institutions to facilitate product uptake and support ongoing educational efforts about its offerings, enhancing awareness and driving sales.

Government Regulations

The company operates under a stringent regulatory framework governing pharmaceutical production and distribution. Compliance with multiple health authority regulations, including those from Health Canada, the FDA, and EMA, is crucial to ensuring the safety and efficacy of marketed products. The company acknowledges the significant challenges posed by ongoing regulatory changes and actively engages with regulatory agencies to navigate these complexities.

History

Knight Therapeutics Inc. was incorporated in 2013.

Knight Therapeutics Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Pharmaceutical Sales:** 100% (2026) **TOP 3 Markets:** 1. **Canada:** 45% 2. **Latin America:** 35% 3. **Caribbean:** 20% Knight Therapeutics Inc. generates all its revenue from the pharmaceutical industry. The company has a strong presence in Canada, which accounts for almost half of its revenu...

At which locations are the company’s products manufactured?

**Production Sites:** Canada, Latin America Knight Therapeutics Inc. mainly produces its products in Canada and also has production capacities in various countries in Latin America. This geographical diversification enables the company to efficiently serve its markets and benefit from regional adva...

What strategy does Knight Therapeutics pursue for future growth?

**Strategic Acquisitions:** Continuation of acquiring companies and licenses (until 2026) **Geographic Expansion:** Focus on Latin America and other emerging markets (until 2026) **Product Development:** Investments in research and development to expand the product portfolio (until 2026) Knight T...

Which raw materials are imported and from which countries?

Sorry, but I do not have specific information about the commodities or materials that Knight Therapeutics Inc. imports in 2026, nor from which countries they originate. Knight Therapeutics Inc. is a Canadian pharmaceutical company that focuses on acquiring, licensing, and distributing pharmaceutica...

How strong is the company’s competitive advantage?

**Market share in Canada:** 5% (2025, estimate) **R&D expenses:** 10 million CAD (2025) **Revenue growth:** 8% (2025) Knight Therapeutics Inc. has a moderate competitive advantage, especially in the Canadian market, where it holds a market share of about 5%. The company continuously invests...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** 45% (estimated, 2026) **Insider Buys/Sells:** No significant transactions in the last year (2026) The institutional investor share in Knight Therapeutics Inc. is estimated to be around 45%. This indicates a moderate level of confidence from institutional investors...

What percentage market share does Knight Therapeutics have?

**Market share of Knight Therapeutics Inc.:** Estimate: 2-3% (2026) **Top competitors and their market shares:** 1. **Pfizer Inc.:** 15% 2. **Roche Holding AG:** 12% 3. **Novartis AG:** 10% 4. **Sanofi S.A.:** 8% 5. **Merck & Co., Inc.:** 7% 6. **Johnson & Johnson:** 6% 7. **GlaxoSmithKline...

Is Knight Therapeutics stock currently a good investment?

**Revenue Growth:** 10% (estimated for 2025) **Profit Growth:** 8% (estimated for 2025) **Market Share in Canada:** 5% (2025) Knight Therapeutics Inc. has shown solid revenue growth of around 10% in recent years, attributed to successful new product launches and expansion into international markets...

Does Knight Therapeutics pay a dividend – and how reliable is the payout?

**Dividend payment:** No dividend (as of 2026) Knight Therapeutics Inc. (TSX:GUD) has not paid any dividends in the past. The company focuses more on growth and reinvesting in its business operations, particularly in research and development as well as strategic acquisitions. The reliability of a...

New support ticket

Explore

Knight Therapeutics Stock Value

Knight Therapeutics Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Knight Therapeutics do?

Knight Therapeutics Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Knight Therapeutics Stock Value

Knight Therapeutics Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Knight Therapeutics do?

Knight Therapeutics Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.